Inflammatory Bowel Disease References

Last updated: 22 July 2026
Reviewed by
  1. Carter MJ, Lobo AJ, Travis SPL; IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004 Sep;53(Suppl 5):v1-16. PMID: 15306569
  2. MedWormhttp://www.medworm.com/rss/index.php/Gastroenterology/17/http://www.medworm.com/rss/medicalfeeds/specialities/Gastroenterology.xml
  3. MedWorm http://www.medworm.com/rss/index.php/Pediatrics/33/ http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics-News.xml
  4. National Guideline Clearinghouse (NGC). Guideline summary: practice parameters for the surgical treatment of ulcerative colitis. Agency for Healthcare, Research and Quality. http://www.guideline.gov. 18 Jul 2011.
  5. Peyrin-Biroulet L, Panes J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol. 2016 Mar 11;14(3):348-354. http://dx.doi.org/10.1016/j.cgh.2015.06.001. Accessed 28 Jun 2016
  6. Gomollón F, Dignass A, Annese V, et al. 3. European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017 Jan;11(1):3-25. doi: 10.1093/ecco-jcc/jjw168. PMID: 27660341
  7. Gionchetti P, Dignass A, Danese S, et al. 3. European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 2: surgical management and special situations. J Crohns Colitis. 2016 Sep 22. doi: 10.1093/ecco-jcc/jjw169. PMID: 27660342
  8. Gastroenterological Society of Australia (GESA). Clinical update for general practitioners and physicians - inflammatory bowel disease. Updated 2018. GESA. http://www.gesa.org.au. 2018. Accessed 02 Aug 2019.
  9. Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017 Jul;11(7):769-784. doi: 10.1093/ecco-jcc/jjx009. Accessed 02 Aug 2019. PMID: 28513805
  10. Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019 Feb;13(2):144-164. doi: 10.1093/ecco-jcc/jjy113. Accessed 02 Aug 2019. PMID: 30137275
  11. Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017 Jun;11(6):649-670. doi: 10.1093/ecco-jcc/jjx008. Accessed 02 Aug 2019. PMID: 28158501
  12. Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018 Mar;53(3):305-353. doi: 10.1007/s00535-018-1439-1. Accessed 02 Aug 2019. PMID: 29429045
  13. National Institute for Health and Care Excellence (NICE). Crohn’s disease: management. NICE. https://www.nice.org.uk. 3 May 2019. Accessed 02 Aug 2019.
  14. National Institute for Health and Care Excellence (NICE). Ustekinumab for moderately to severely active Crohn’s disease after previous treatment. NICE. https://www.nice.org.uk. 12 Jul 2017. Accessed 08 Aug 2019.
  15. Sturm A, Maaser C, Calabrese E, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019 Mar;13(3):273-284. doi: 10.1093/ecco-jcc/jjy114. Accessed 02 Aug 2019. PMID: 30137278
  16. U.S. Food & Drug Administration (US FDA). Biosimilar product information. US FDA. https://www.fda.gov/. 24 Feb 2020. Accessed 28 Feb 2020.
  17. Feuerstein JD, Isaacs KL, Schneider Y, et al; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020 Jan 13. pii: S0016-5085(20)30018-4. doi: 10.1053/j.gastro.2020.01.006. Accessed 20 Mar 2020. PMID: 31945371
  18. Lichtenstein GR, Loftus EV, Afzali A, et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2025 Jun;120(6):1225-1264. doi: 10.14309/ajg.0000000000003465. Accessed 16 Jul 2025. PMID: 40701562
  19. Singh S, Fumery M, Sandborn WJ, et al. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther. 2018 Aug;48(4):394-409. doi: 10.1111/apt.14852. Accessed 24 Mar 2020. PMID: 29920733
  20. Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis. 2020 Jan 1;14(1):4-22. doi: 10.1093/ecco-jcc/jjz180. Accessed 20 Mar 2020. PMID: 31711158
  21. Sulz MC, Burri E, Michetti P, et al. Treatment algorithms for Crohn's disease. Digestion. 2020 Mar 13:1-15. doi: 10.1159/000506364. Accessed 15 May 2020. PMID: 32172251
  22. Clarke WT, Feuerstein JD. Colorectal cancer surveillance in inflammatory bowel disease: practice guidelines and recent developments. World J Gastroenterol. 2019 Aug 14;25(30):4148-4157. doi: 10.3748/wjg.v25.i30.4148. Accessed 24 Nov 2021. PMID: 31435169
  23. Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology. 2021 Jun;160(7):2496-2508. doi: 10.1053/j.gastro.2021.04.022. Accessed 25 Nov 2021. PMID: 34051983
  24. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019 Mar;114(3):384-413. doi: 10.14309/ajg.0000000000000152. Accessed 24 Nov 2021. PMID: 30840605
  25. Sandborn WJ, Feagan BG, D'Haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. Accessed 24 Nov 2021. PMID: 34587385
  26. Zeposia highlights of prescribing information. U.S. Food & Drug Administration. https://www.accessdata.fda.gov. May 2021. Accessed 22 Nov 2021.
  27. Adamina M, Minozzi S, Warusavitarne J, et al. ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment. J Crohns Colitis. 2024 Oct;18(10):1556-1582. doi: 10.1093/ecco-jcc/jjae089. Accessed 18 Apr 2022. PMID: 38878002
  28. Bischoff SC, Escher J, Hébuterne X, et al. ESPEN practical guideline: clinical nutrition in inflammatory bowel disease. Clin Nutr. 2020 Mar;39(3):632-653. doi: 10.1016/j.clnu.2019.11.002. PMID: 32029281
  29. De Simone B, Davies J, Chouillard E, et al. WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting. World J Emerg Surg. 2021 May;16(1):23. doi: 10.1186/s13017-021-00362-3. PMID: 33971899
  30. Holubar SD, Lightner AL, Poylin V, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the surgical management of ulcerative colitis. Dis Colon Rectum. 2021 Jul;64(7):783-804. doi: 10.1097/DCR.0000000000002037. PMID: 33853087
  31. Ko CW, Singh S, Feuerstein JD, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019 Feb;156(3):748-764. doi: 10.1053/j.gastro.2018.12.009. PMID: 30576644
  32. Kucharzik T, Ellul P, Greuter T, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021 Jun;15(6):879-913. doi: 10.1093/ecco-jcc/jjab052. PMID: 33730753
  33. Lightner AL, Vogel JD, Carmichael JC, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the surgical management of Crohn’s disease. Dis Colon Rectum. 2020 Aug;63(8):1028-1052. doi: 10.1097/DCR.0000000000001716. PMID: 32692069
  34. Murthy SK, Feuerstein JD, Nguyen GC, et al. AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review. Gastroenterology. 2021 Sep;161(3):1043-1051. doi: 10.1053/j.gastro.2021.05.063. Accessed 18 Apr 2022. PMID: 34416977
  35. Spinelli A, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment. J Crohns Colitis. 2022 Feb;16(2):179-189. doi: 10.1093/ecco-jcc/jjab177. PMID: 34635910
  36. Hibi T. Risankizumab for Crohn's disease. Lancet. 2022 May 28;399(10340):1992-1993. doi: 10.1016/S0140-6736(22)00628-6. PMID: 35644143
  37. U.S. Food & Drug Administration (US FDA). Abrilada highlights of prescribing information. US FDA. https://www.fda.gov/. Nov 2019. Accessed 18 Aug 2022.
  38. Cohen RD, Stein AC. Management of moderate to severe ulcerative colitis in adults. UpToDate. https://www.uptodate.com. 20 Sep 2023. Accessed 25 Jul 2023.
  39. Gaertner WB, Burgess PL, Davids JS, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of anorectal abscess, fistula-in-ano, and rectovaginal fistula. Dis Colon Rectum. 2022 Aug;65(8):964-985. doi: 10.1097/DCR.0000000000002473. PMID: 35732009
  40. Hashash JA, Regueiro M. Medical management of moderate to severe Crohn disease in adults. UpToDate. https://www.uptodate.com. 24 Jun 2025. Accessed 15 Nov 2023.
  41. Lee SH, Kwon JE, Cho ML. Immunological pathways of inflammatory bowel disease. Intest Res. 2018 Jan;16(1):26-42. doi: 10.5217/ir.2018.16.1.26. Accessed 25 Jul 2023. PMID: 29422795
  42. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): colorectal cancer screening. Version 2.2025. NCCN. https://www.nccn.org/. 24 Jun 2025. Accessed 25 Jul 2023.
  43. National Institute for Health Care and Excellence (NICE). Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn’s disease or adenomas. NICE. https://www.nice.org.uk. 20 Sep 2022. Accessed 25 Jul 2023.
  44. Peppercorn MA, Cheifetz AS. Definitions, epidemiology, and risk factors for inflammatory bowel disease. UpToDate. https://www.uptodate.com. 10 Jul 2023.
  45. Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022 Jan 28;16(1):2-17. doi: 10.1093/ecco-jcc/jjab178. Accessed 25 Jul 2023. PMID: 34635919
  46. Rogler G, Biedermann L, Schari M. New insights into the pathophysiology of inflammatory bowel disease: microbiota, epigenetics and common signalling pathways. Swiss Med Wkly. 2018 Mar;148:w14599. doi: 10.4414/smw.2018.14599. PMID: 29566254
  47. Saez A, Herrero-Fernandez B, Gomez-Bris R, et al. Pathophysiology of inflammatory bowel disease: innate immune system. Int J Mol Sci. 2023 Jan;24(2):1526. doi: 10.3390/ijms24021526. PMID: 36675038
  48. Shah J, Dutta U, Das A, et al. Relationship between Mayo endoscopic score and histological scores in ulcerative colitis: a prospective study. JGH Open. 2020 Jun;4(3):382-386. doi: 10.1002/jgh3.12260. PMID: 32514441
  49. Singh S, Ananthakrishnan AN, Nguyen NH, et al. AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis. Gastroenterology. 2023 Mar;164(3):344-372. doi: 10.1053/j.gastro.2022.12.007. PMID: 36822736
  50. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. PMID: 33359090
  51. Gordon H, Biancone L, Fiorino G, et al. ECCO guidelines on inflammatory bowel disease and malignancies. J Crohns Colitis. 2023 Jun;17(6):827-854. doi: 10.1093/ecco-jcc/jjac187. PMID: 36528797
  52. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease. Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. PMID: 31562236
  53. D’Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023 Jun;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. PMID: 37379135
  54. Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomized, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023 Apr;401(10383):1159-1171. doi: 10.1016/S0140-6736(23)00061-2. PMID: 36871574
  55. Honap S, Agorogianni A, Colwill MJ, et al. JAK inhibitors for inflammatory bowel disease: recent advances. Frontline Gastroenterol. 2023 Sep 14;15(1):59-69. doi: 10.1136/flgastro-2023-102400. PMID: 38487554
  56. Caldera F, Kane S, Long M, et al. AGA clinical practice update on noncolorectal cancer screening and vaccinations in patients with inflammatory bowel disease: expert review. Clin Gastroenterol Hepatol. 2025 Apr;23(5):695-706. doi: 10.1016/j.cgh.2024.12.011. Accessed 19 Jul 2025. PMID: 39800200
  57. East JE, Gordon M, Nigam GB, et al. British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease. Gut. 2025 Apr 30:1-34. doi: 10.1136/gutjnl-2025-335023.
  58. Gordon H, Minozzi S, Kopylov U, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2024 Oct;18(10):1531-1555. doi: 10.1093/ecco-jcc/jjae091. PMID: 38877997
  59. Peppercorn MA, Kane SV. Crohn disease in adults. UpToDate. https://www.uptodate.com. 02 Jul 2025.
  60. Svolos V, Gordon H, Lomer MCE, et al. ECCO consensus on dietary management of inflammatory bowel disease. J Crohns Colitis. 2025 Jul:jjaf122. doi: 10.1093/ecco-jcc/jjaf122. PMID: 40650933
  61. Wong SY, Rowan C, Brockmans ED, et al. Perianal fistulizing Crohn’s disease-associated anorectal and fistula cancers: systematic review and expert consensus. Clin Gastroenterol Hepatol. 2025 May;23(6):927-945.e2. doi: 10.1016/j.cgh.2024.05.029. PMID: 38871152
  62. Penner RM. Management of Crohn disease after surgical resection. UpToDate. https://www.uptodate.com. 24 Mar 2025.
  63. Agrawal M, Jess T. Implications of the changing epidemiology of inflammatory bowel disease in a changing world. United European Gastroenterol J. 2022 Dec;10(10):1113-1120. doi: 10.1002/ueg2.12317. PMID: 36251359
  64. Aniwan S, Santiago P, Loftus EV Jr, et al. The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries. United European Gastroenterol J. 2022 Dec;10(10):1063-1076. doi: 10.1002/ueg2.12350. PMID: 36479863
  65. National Institute for Health and Care Excellence (NICE). Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. NICE. https://www.nice.org.uk. 02 Oct 2013.
  66. Queensland Government Metro South Health. Refer your patient. Inflammatory bowel disease. Queensland Government Metro South Health. https://refer.metrosouth.health.qld.gov.au. 2026.